MARKET

RDHL

RDHL

Redhill Biopharm
NASDAQ
2.190
+0.060
+2.82%
After Hours: 2.100 -0.09 -4.11% 19:54 07/11 EDT
OPEN
2.140
PREV CLOSE
2.130
HIGH
2.190
LOW
2.114
VOLUME
11.50K
TURNOVER
--
52 WEEK HIGH
20.28
52 WEEK LOW
1.710
MARKET CAP
5.03M
P/E (TTM)
-0.3264
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RDHL last week (0630-0704)?
Weekly Report · 4d ago
RedHill Biopharma Initiates Phase 2 Prostate Cancer Study
TipRanks · 07/01 16:28
RedHill initiates recruitment for expanded Phase 2 opaganib/darolutamide study
TipRanks · 07/01 16:10
RedHill Biopharma Announces The Initiation Of Patient Recruitment Into The Phase 2 Study Evaluating The Efficacy Of Opaganib3 In Combination With Darolutamide4 In Men With Metastatic Castrate-Resistant Prostate Cancer
Benzinga · 07/01 16:03
Weekly Report: what happened at RDHL last week (0623-0627)?
Weekly Report · 06/30 10:23
RedHill Biopharma Secures $10 Million Market Purchase Agreement with Alumni Capital
TipRanks · 06/25 21:33
Weekly Report: what happened at RDHL last week (0616-0620)?
Weekly Report · 06/23 10:19
Weekly Report: what happened at RDHL last week (0609-0613)?
Weekly Report · 06/16 10:23
More
About RDHL
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

Webull offers RedHill Biopharma Ltd (ADR) stock information, including NASDAQ: RDHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDHL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RDHL stock methods without spending real money on the virtual paper trading platform.